Nuvalent (Nuvalent) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Nuvalent Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Nuvalent's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Nuvalent could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Nuvalent's Cash-to-Debt or its related term are showing as below:

NUVL' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.39 Med: No Debt Max: No Debt
Current: No Debt

During the past 5 years, Nuvalent's highest Cash to Debt Ratio was No Debt. The lowest was 1.39. And the median was No Debt.

NUVL's Cash-to-Debt is ranked better than
99.74% of 1540 companies
in the Biotechnology industry
Industry Median: 6.495 vs NUVL: No Debt

Nuvalent Cash-to-Debt Historical Data

The historical data trend for Nuvalent's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Nuvalent Cash-to-Debt Chart

Nuvalent Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

1.39

4.62

No Debt

Nuvalent Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial												No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Nuvalent's Cash-to-Debt

For the Biotechnology subindustry, Nuvalent's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuvalent's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvalent's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Nuvalent's Cash-to-Debt falls into.

Nuvalent Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Nuvalent's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Nuvalent had no debt ⁽¹⁾.

Nuvalent's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Nuvalent had no debt ⁽¹⁾.

Nuvalent (NAS:NUVL) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Nuvalent Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Nuvalent's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvalent (Nuvalent) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvalent Inc (NAS:NUVL) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Broadway, 14th Floor, Cambridge, MA, USA, 02142

Website

https://www.nuvalent.com

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Executives

Matthew Shair	director	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Deborah Ann Miller	officer: Chief Legal Officer	C/O NUVALENT, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Anna Protopapas	director	MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Darlene Noci	officer: See Remarks	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Alexandra Balcom	officer: Chief Financial Officer	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Christopher Durant Turner	officer: Chief Medical Officer	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Deerfield Mgmt L.p.	director, 10 percent owner, other: * Director by deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p.	director, 10 percent owner, other: Director by Deputization	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
James E Flynn	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Hack Andrew A. F.	director	300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Michael L. Meyers	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Emily Conley	director	C/O NUVALENT, INC., ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA 02142
Deerfield Private Design Fund Iv, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017
Robert Bowers Jackson	director	C/O NUVALENT, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
James Richard Porter	director, officer: President and CEO	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142